Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business UpdateGlobeNewsWire • 11/04/26
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private PlacementGlobeNewsWire • 11/02/26
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private PlacementGlobeNewsWire • 10/28/26
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private PlacementGlobeNewsWire • 10/27/26
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update TranscriptSeeking Alpha • 10/20/26
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock SurgingBarrons • 10/20/26
Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots HigherInvestors Business Daily • 10/20/26
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar ManiaGlobeNewsWire • 10/20/26
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating UpgradeSeeking Alpha • 09/24/26
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania TranscriptSeeking Alpha • 09/23/26
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga • 09/16/26
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical ProgramGlobeNewsWire • 08/24/26
Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy FranchiseSeeking Alpha • 08/21/26
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business UpdateGlobeNewsWire • 08/05/26
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?The Motley Fool • 07/12/26
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewsWire • 05/20/26
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business UpdateGlobeNewsWire • 05/07/26